Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2023 | $3.00 → $1.00 | Buy → Neutral | B. Riley Securities |
| 8/30/2023 | $3.00 | Buy | B. Riley Securities |
| 12/22/2022 | $3.00 | Overweight | Cantor Fitzgerald |
| 12/12/2022 | $3.00 | Overweight | Piper Sandler |
| 12/14/2021 | $21.00 → $11.00 | Buy | HC Wainwright & Co. |
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on October 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 271,764 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees ente
BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter ended September 30, 2024 and present results from its concluded Phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on Wednesday, November 13, 2024. The company will host a conference call and webcast on the same day at 8:00 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast and accom
BOSTON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on September 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 744,468 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees en
BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter ended September 30, 2024 and present results from its concluded Phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on Wednesday, November 13, 2024. The company will host a conference call and webcast on the same day at 8:00 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast and accom
First U.S. commercial sales of XOLREMDI™ (mavorixafor) following April 2024 FDA approval Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full trial results expected in November 2024 Initiated global, pivotal Phase 3 trial of mavorixafor in chronic neutropenia Conference call to be hosted today at 8:30 a.m. ET BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the second quarter ended June 30, 2024 and highlighted key recent and upcoming expected milestones. Paula Ragan, Ph.D., President and Chief Executi
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the second quarter ended June 30, 2024 and provide corporate updates on Thursday, August 8, 2024. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-225-9448 from the United States or 1-203-518-9708 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.co
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent director to the company's Board of Directors. "We are thrilled to welcome Keith to the X4 Board of Directors," said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. "With his broad and deep experience in commercialization, international operations, supply chain, and business strategy, as well as his recent successful global launch of a rare disease product, we believe it is a great time for him to be joining X4 as a director a
A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November 3, 2022 BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced the appointment of Mark Baldry to the position of Chief Commercial Officer. In this key role, Mr. Baldry will lead all pre-commercial and product launch efforts for the company's lead therapeutic candidate, mavorixafor, a small molecule being developed as a once-daily oral therapy for chronic neutropenic disorders, including WHIM syndrome.
WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. "As we prepare for late-stage clinical development for our TED programs, we are excited to add Carrie to the Viridian team" said Jonathan Violin, Ph.D., Viridian Therapeutics' President and CEO. "Carrie's extensive experience in a wide range of operational activities supporting product development and approval will be tremendously valuable to our expanding
S-8 - X4 Pharmaceuticals, Inc (0001501697) (Filer)
8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)
8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)
4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)
Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity
B. Riley Securities downgraded X4 Pharmaceuticals from Buy to Neutral and set a new price target of $1.00 from $3.00 previously
B. Riley Securities resumed coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $3.00
Cantor Fitzgerald initiated coverage of X4 Pharmaceuticals with a rating of Overweight and set a new price target of $3.00
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains $5 price target.
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date. Durable mean ANC levels above the lower limit of normal for CN were achieved for participants on mavorixafor monotherapy at Months 3 and 6.
SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)
SC 13G - X4 Pharmaceuticals, Inc (0001501697) (Subject)
SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)